KN 387271
Alternative Names: BAY 7271; BAY-387271; KN 38-7271Latest Information Update: 20 Aug 2015
At a glance
- Originator Bayer HealthCare
- Developer KeyNeurotek Pharmaceuticals AG
- Class Neuroprotectants; Small molecules
- Mechanism of Action Cannabinoid receptor agonists; Cannabinoid receptor CB1 agonists; Cannabinoid receptor CB2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Brain injuries; Stroke
Most Recent Events
- 25 May 2011 Phase I development is ongoing in Germany
- 25 May 2011 Phase II development is ongoing in Europe
- 16 Dec 2009 Efficacy data from a phase II trial in traumatic brain injury released by KeyNeurotek